RxDoctor Payments Data

Phillip Dixon, MD

Internal Medicine · Reidsville, NCNPI 1689296444

Payments from drug & device makers

$1,994in general payments, 2019–2025

Across 101 payments — averaging $19.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$321
  • Lilly USA, LLC$285
  • AstraZeneca$260
  • AbbVie$242
  • Johnson & Johnson$130
  • GSK$117
  • plus $638 from 15 others

What the payments were for

  • Food & beverage$1,994100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,994 in reported general payments places this provider in the 80th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$46,354
Medicare patients
147
Services billed
478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide93$130,904
OzempicSemaglutide117$126,960
JardianceEmpagliflozin91$77,286
FarxigaDapagliflozin Propanediol82$59,165
EliquisApixaban39$31,019
EntrestoSacubitril/Valsartan23$20,433
Breztri AerosphereBudesonide/Glycopyr/Formoterol29$18,393
CreonLipase/Protease/Amylase14$17,488
MyrbetriqMirabegron19$11,569
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,562
SymbicortBudesonide/Formoterol Fumarate26$6,491
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$6,118
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$5,113
BrilintaTicagrelor11$5,043
Varenicline Tartrate16$4,736

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$285$130,90493 claims
Novo NordiskOzempic$321$126,960117 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta$260$89,092148 claims
Boehringer IngelheimJardiance, Stiolto Respimat$45$82,400102 claims
PfizerEliquis$57$31,01939 claims
NovartisEntresto$50$20,43323 claims
AbbVieCreon, Synthroid$242$18,54027 claims
GSKTrelegy Ellipta, Anoro Ellipta$117$13,68124 claims
Astellas Pharma US IncMyrbetriq$70$11,56919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Reidsville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →